Fernando Arias-Mendoza1, Franklyn Howe2,
Marion Stubbs3, Seung-Cheol Lee4, Geoffrey S. Payne5,
Kristen Zakian6, Hamed Mojahed1, Harish Poptani4,
Mary McLean3, Amita Shukla-Dave6, Nicholas R. Maisey5,
Owen A. O'Connor7,8, Ruth Pettengell9, Steven J.
Schuster4, David Cunningham10, John R. Griffiths3,
Jerry D. Glickson4, Martin O. Leach5, Jason A. Koutcher6,
Arend Heerschap11, Truman R. Brown1
1Radiology, Columbia University, New
York, NY, United States; 2Radiology, St. George's Hospital,
London, United Kingdom; 3Radiology, Cambridge University,
Cambridge, United Kingdom; 4Radiology, University of Pennsylvania,
Philadelphia, PA, United States; 5Radiology, Institute of Cancer
Research, London, United Kingdom; 6Radiology, Memorial Sloan
Kettering Cancer Center, New York, NY, United States; 7Medical
Oncology, Columbia University, New York, NY, United States; 8Medical
Oncology, New York University, New York, NY, United States; 9Medical
Oncology, St. George's Hospital, London, United Kingdom; 10Medical
Oncology, Institute of Cancer Research, London, United Kingdom; 11Radiology,
Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
In vivo localized, 31P
and 1H MRS was acquired in tumors of non-Hodgkins lymphoma
patients before treatment, and the phosphoethanolamine plus
phosphocholine-to-nucleoside triphosphate and total choline-to-water ratios
determined in the 31P and 1H tumor spectra respectively.
In these preliminary data, the pretreatment ratios showed a linear
correlation (y=0.16x 0.77, r2=0.7, p<0.005). This correlation and the
increased sensitivity of 1H observations in comparison to those of
31P suggests that the prediction of therapeutic outcome by MR
technology can be improved by the addition of 1H spectroscopy to
the in vivo MR observations of NHL
patients.